Surrozen Inc. Common Stock

Surrozen Inc. a clinical stage biotechnology company discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas including diseases of the intestine liver retina cornea lung kidney cochlea skin pancreas and central nervous system. Its products in pipeline include SZN-043 a hepatocyte-specific R-spondin mimetic bispecific fusion protein which is in Phase 1b clinical trial for the treatment of severe liver diseases including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326 a bi-specific antibody which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease Frizzled and LRP receptors. The company also develops SZN-413 a Fzd4 targeted bi-specific antibody which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research develop and commercialize Fzd4 bi-specific antibodies. Surrozen Inc. was founded in 2015 and is based in South San Francisco California.